MIRUM PHARMACEUTICALS INC

MIRMNASDAQ

🏆 #1120 by market capEarnings Nov 3US Equity

$99.91▲ $1.71 (+1.71%)

Live

1h▲ 0.5%

24h▲ 1.7%

7d▼ 5.5%

14d▼ 7.2%

30d▼ 16.0%

1y▲ 54.5%

🏦Market Cap

$6.09B

Small Cap

📈Revenue Growth (YoY)

+54.7%

High Growth

📊Gross Margin

81.7%

High

💵FCF Margin

-74.1%

Thin

⚖️P/S Ratio

9.7x

Elevated

Otter Score

Fair

Trading Snapshot

Day Range: $99.05 – $100.54
52-Week Range: $63.23 – $130.00
Volume: $3.77B
Avg Volume: $4.70B
Shares Outstanding: 61.0M
Next Earnings: Sep 17, 2026

Fundamentals Snapshot

Annual Revenue: $521M
Last Q Revenue: $176M
P/E Ratio: -6.7
P/S Ratio: 9.7x
EPS (TTM): $-13.57
Dividend Yield: 0.00%

Why Investors Own MIRM

✓High-growth profile — revenue up +26.5% YoY with expanding US Equity exposure.
✓Healthy economics — 48% gross margin and 13% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$521M▲ +31.1% YoY

Gross Margin (TTM)

48.0%▲ +4.3% YoY

Operating Income (TTM)

$168M▲ +31.1% YoY

Free Cash Flow (TTM)

$68M▲ +31.1% YoY

About MIRUM PHARMACEUTICALS INC

Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.

🦦